We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Arcus Biosciences Inc | NYSE:RCUS | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.18 | -1.35% | 13.15 | 13.55 | 12.97 | 13.23 | 889,783 | 01:00:00 |
From Jul 2024 to Jan 2025
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended June 30th, 2024.
Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 287576. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725633260/en/
Investor Inquiries Pia Eaves VP of Investor Relations & Strategy (617) 459-2006 peaves@arcusbio.com
Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com
1 Year Arcus Biosciences Chart |
1 Month Arcus Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
